ACR appropriateness criteria prostate cancer - Pretreatment detection, staging, and surveillance

Steven C. Eberhardt, Scott Carter, David D. Casalino, Gregory Merrick, Steven J. Frank, Alexander R. Gottschalk, John R. Leyendecker, Paul L. Nguyen, Aytekin Oto, Christopher Porter, Erick M. Remer, Seth A. Rosenthal

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Prostate cancer is the most common noncutaneous male malignancy in the United States. The use of serum prostate-specific antigen as a screening tool is complicated by a significant fraction of nonlethal cancers diagnosed by biopsy. Ultrasound is used predominately as a biopsy guidance tool. Combined rectal examination, prostate-specific antigen testing, and histology from ultrasound-guided biopsy provide risk stratification for locally advanced and metastatic disease. Imaging in low-risk patients is unlikely to guide management for patients electing up-front treatment. MRI, CT, and bone scans are appropriate in intermediate-risk to high-risk patients to better assess the extent of disease, guide therapy decisions, and predict outcomes. MRI (particularly with an endorectal coil and multiparametric functional imaging) provides the best imaging for cancer detection and staging. There may be a role for prostate MRI in the context of active surveillance for low-risk patients and in cancer detection for undiagnosed clinically suspected cancer after negative biopsy results. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.

Original languageEnglish (US)
Pages (from-to)83-92
Number of pages10
JournalJournal of the American College of Radiology
Volume10
Issue number2
DOIs
StatePublished - Jan 1 2013

Fingerprint

Prostatic Neoplasms
Biopsy
Prostate-Specific Antigen
Neoplasms
Guidelines
Neoplasm Staging
Expert Testimony
Therapeutics
Prostate
Histology
Bone and Bones
Serum

Keywords

  • Appropriateness Criteria
  • detection
  • imaging
  • prostate cancer
  • staging

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Eberhardt, S. C., Carter, S., Casalino, D. D., Merrick, G., Frank, S. J., Gottschalk, A. R., ... Rosenthal, S. A. (2013). ACR appropriateness criteria prostate cancer - Pretreatment detection, staging, and surveillance. Journal of the American College of Radiology, 10(2), 83-92. https://doi.org/10.1016/j.jacr.2012.10.021

ACR appropriateness criteria prostate cancer - Pretreatment detection, staging, and surveillance. / Eberhardt, Steven C.; Carter, Scott; Casalino, David D.; Merrick, Gregory; Frank, Steven J.; Gottschalk, Alexander R.; Leyendecker, John R.; Nguyen, Paul L.; Oto, Aytekin; Porter, Christopher; Remer, Erick M.; Rosenthal, Seth A.

In: Journal of the American College of Radiology, Vol. 10, No. 2, 01.01.2013, p. 83-92.

Research output: Contribution to journalArticle

Eberhardt, SC, Carter, S, Casalino, DD, Merrick, G, Frank, SJ, Gottschalk, AR, Leyendecker, JR, Nguyen, PL, Oto, A, Porter, C, Remer, EM & Rosenthal, SA 2013, 'ACR appropriateness criteria prostate cancer - Pretreatment detection, staging, and surveillance', Journal of the American College of Radiology, vol. 10, no. 2, pp. 83-92. https://doi.org/10.1016/j.jacr.2012.10.021
Eberhardt, Steven C. ; Carter, Scott ; Casalino, David D. ; Merrick, Gregory ; Frank, Steven J. ; Gottschalk, Alexander R. ; Leyendecker, John R. ; Nguyen, Paul L. ; Oto, Aytekin ; Porter, Christopher ; Remer, Erick M. ; Rosenthal, Seth A. / ACR appropriateness criteria prostate cancer - Pretreatment detection, staging, and surveillance. In: Journal of the American College of Radiology. 2013 ; Vol. 10, No. 2. pp. 83-92.
@article{427f345334c5406883eb3ef57b3c2814,
title = "ACR appropriateness criteria prostate cancer - Pretreatment detection, staging, and surveillance",
abstract = "Prostate cancer is the most common noncutaneous male malignancy in the United States. The use of serum prostate-specific antigen as a screening tool is complicated by a significant fraction of nonlethal cancers diagnosed by biopsy. Ultrasound is used predominately as a biopsy guidance tool. Combined rectal examination, prostate-specific antigen testing, and histology from ultrasound-guided biopsy provide risk stratification for locally advanced and metastatic disease. Imaging in low-risk patients is unlikely to guide management for patients electing up-front treatment. MRI, CT, and bone scans are appropriate in intermediate-risk to high-risk patients to better assess the extent of disease, guide therapy decisions, and predict outcomes. MRI (particularly with an endorectal coil and multiparametric functional imaging) provides the best imaging for cancer detection and staging. There may be a role for prostate MRI in the context of active surveillance for low-risk patients and in cancer detection for undiagnosed clinically suspected cancer after negative biopsy results. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.",
keywords = "Appropriateness Criteria, detection, imaging, prostate cancer, staging",
author = "Eberhardt, {Steven C.} and Scott Carter and Casalino, {David D.} and Gregory Merrick and Frank, {Steven J.} and Gottschalk, {Alexander R.} and Leyendecker, {John R.} and Nguyen, {Paul L.} and Aytekin Oto and Christopher Porter and Remer, {Erick M.} and Rosenthal, {Seth A.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/j.jacr.2012.10.021",
language = "English (US)",
volume = "10",
pages = "83--92",
journal = "Journal of the American College of Radiology",
issn = "1558-349X",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - ACR appropriateness criteria prostate cancer - Pretreatment detection, staging, and surveillance

AU - Eberhardt, Steven C.

AU - Carter, Scott

AU - Casalino, David D.

AU - Merrick, Gregory

AU - Frank, Steven J.

AU - Gottschalk, Alexander R.

AU - Leyendecker, John R.

AU - Nguyen, Paul L.

AU - Oto, Aytekin

AU - Porter, Christopher

AU - Remer, Erick M.

AU - Rosenthal, Seth A.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Prostate cancer is the most common noncutaneous male malignancy in the United States. The use of serum prostate-specific antigen as a screening tool is complicated by a significant fraction of nonlethal cancers diagnosed by biopsy. Ultrasound is used predominately as a biopsy guidance tool. Combined rectal examination, prostate-specific antigen testing, and histology from ultrasound-guided biopsy provide risk stratification for locally advanced and metastatic disease. Imaging in low-risk patients is unlikely to guide management for patients electing up-front treatment. MRI, CT, and bone scans are appropriate in intermediate-risk to high-risk patients to better assess the extent of disease, guide therapy decisions, and predict outcomes. MRI (particularly with an endorectal coil and multiparametric functional imaging) provides the best imaging for cancer detection and staging. There may be a role for prostate MRI in the context of active surveillance for low-risk patients and in cancer detection for undiagnosed clinically suspected cancer after negative biopsy results. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.

AB - Prostate cancer is the most common noncutaneous male malignancy in the United States. The use of serum prostate-specific antigen as a screening tool is complicated by a significant fraction of nonlethal cancers diagnosed by biopsy. Ultrasound is used predominately as a biopsy guidance tool. Combined rectal examination, prostate-specific antigen testing, and histology from ultrasound-guided biopsy provide risk stratification for locally advanced and metastatic disease. Imaging in low-risk patients is unlikely to guide management for patients electing up-front treatment. MRI, CT, and bone scans are appropriate in intermediate-risk to high-risk patients to better assess the extent of disease, guide therapy decisions, and predict outcomes. MRI (particularly with an endorectal coil and multiparametric functional imaging) provides the best imaging for cancer detection and staging. There may be a role for prostate MRI in the context of active surveillance for low-risk patients and in cancer detection for undiagnosed clinically suspected cancer after negative biopsy results. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.

KW - Appropriateness Criteria

KW - detection

KW - imaging

KW - prostate cancer

KW - staging

UR - http://www.scopus.com/inward/record.url?scp=84928096739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928096739&partnerID=8YFLogxK

U2 - 10.1016/j.jacr.2012.10.021

DO - 10.1016/j.jacr.2012.10.021

M3 - Article

C2 - 23374687

AN - SCOPUS:84928096739

VL - 10

SP - 83

EP - 92

JO - Journal of the American College of Radiology

JF - Journal of the American College of Radiology

SN - 1558-349X

IS - 2

ER -